Chief Physician, Professor and Doctoral Supervisor. He specializes in imaging diagnosis of abdominal diseases, especially the diagnosis of hepatic, pancreatic and gastrointestinal diseases.He has published more than 70 papers as the first author, corresponding author or co-corresponding author, including over 50 SCI-indexed papers with a total impact factor exceeding 200. Publications include flagship journal in hepatology Hepatology and top imaging journal Radiology. He has undertaken a total of 8 research projects, including 1 sub-project of the National Key Research and Development Program, 2 projects funded by the National Natural Science Foundation of China, and 1 key project of the Shanghai Health and Family Planning Commission. He has won institutional, provincial and ministerial research awards 8 times and obtained 2 invention patents. He has participated in the formulation of more than 10 national expert consensuses or guidelines, and is the lead author of the Chinese Medical Association Expert Consensus: Clinical Application of Hepatobiliary-Specific MRI Contrast Agent Gadoxetic Acid Disodium (2016 Chinese Version). He contributed to the writing of the Chinese Society of Clinical Oncology (CSCO) Gastric Cancer Diagnosis and Treatment Guidelines (2021/2022/2023/2024 Editions), being responsible for the imaging section. The 2021 and 2023 editions were simultaneously released in English and published in Cancer Communications, with 384 citations. He also participated in compiling the Expert Consensus on Perioperative Treatment of Resectable Advanced Colorectal Cancer (2019), Expert Consensus on Hepatic CT Application of Iomeprol (Iodine Concentration 400 mg/ml), Expert Consensus on Standardized Procedures for Imaging Examination and Diagnosis of Gastric Cancer (2022 Edition), Chinese Expert Consensus on Conversion Therapy and Perioperative Treatment of Primary Liver Cancer (2024 Edition), and other documents.